Disc Medicine Licenses Mabwell’s Monoclocal Antibodies

Disc Medicine has inked a licensing agreement with Mabwell Therapeutics for a portfolio of novel monoclonal antibodies used to modulate iron in the blood for diseases such as polycythemia vera, a type of blood cancer, or beta-thalassemia, an inherited blood disorder that causes reduced hemoglobin.

The deal includes the drug candidate MWTX-003, for which the FDA has already accepted an Investigational New Drug application. Disc is planning a phase 1 trial in healthy volunteers in the second half of 2023.

Disc will have exclusive rights to develop and commercialize MWTX-003 in the United States, Europe, and other territories outside of China and Southeast Asia. Mabwell will receive an upfront cash payment of $10 million, in addition to development and commercial milestones for a total of up to $412.5 million and tiered royalties on sales.